Ann: RP11 Drug Candidate Progressing to Mid-Stage Human Trials, page-15

According to a new GlobaData report, almost half of all strategic alliances over the past 5 years (2019-2023), in the Asia Pacific region, centred on oligonucleotides.

Oligonucleotides accounted for 28 of the 59 strategic alliances in the report, which covered Australia, China, Japan and South Korea. The highest development stage for these deals was Phase 3.

The top deal seen, for antisense RNAi oligonucleotides, was a US$1.3bn deal between Hansoh Pharmaceutical Group from China and US-based Silence Therapeutics.

According to a pharma analyst at GlobalData, as the growing pipeline of RNA therapeutics brings new treatment approaches for unmet needs, we will see more partnerships for oligonucleotides.

“RNA therapies hold great promise for combating human diseases such as infectious diseases, cancer, neurodegeneration, metabolic disorders and rare genetic diseases.”

https://www.globaldata.com/media/ph...erapies-major-apac-countries-says-globaldata/

https://www.fiercebiotech.com/biote...-continues-charge-into-sirna-silence-r-d-pact